J B Chemicals & Pharmaceuticals Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/p4n2mk4nevdg6t4iwfurr6gn.pdf

Key Takeaways


India Business Transformation

Chopra: "this have never happened in the history of Indian pharma market and if it has to happen I think J.B. will be the only company to climb more ranks"

Sanzyme & Azmarda: The Two Big Bets

Sanzyme (Probiotics)

Kataria: “...suppose we are making say 50 Crores to 60 Crores today with 600 Crores sort of acquisition so three or four years down the line if this business starts making 100 Crores we are already making 15% to 16%, treasuries are not going to give you 15% to 16% even three years down the line...”

Azmarda (Heart Failure)

Khanna: "Going forward certainly the competition is going to intensify... however, having said that if you see what has happened in the Indian market over the last four years whenever a molecule has gone off patent... in most cases the volumes have actually gone up three times, which have actually helped to neutralize any price impact..."

Portfolio & Therapy Expansion

Chopra: "actually friends it is not a five brand, we are talking of 50 SKUs put together in this franchises"

International & CMO Business

Chopra: "We have the capability, we have the capacity, we know how in terms of the relationship that we enjoy with all the big players so why Indian population, Indian patients should be denied with world class Lozenges that today many of the consumers globally have been consuming from the house of J.B."

US Strategy: Guarded & Selective

Kataria: "I think as far as US is concerned so far the only thing we will maintain is the success is being extremely guarded and conservative right, that is the major difference between us and some of our peers..."

Margins, Costs & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
India IPM rankEnter top 20 companiesNo date given
Domestic revenue contributionIncrease from 50% to 60% of total businessNo date given
Chronic portfolio contributionIncrease to 55%No date given
Cilacar franchise revenueReach ₹1,000 CrNext 5 years
New product revenueHalf a dozen products generating ₹12–14 Cr each, totaling ~₹100 CrNext 18–24 months
Per person productivityReach ₹6–8 lakhs (from ~₹5.6 lakhs)No date given
MR productivity upliftAdd ₹1.5–2 lakhs in lower-productivity geographies18–24 months
Manpower additionZero net addition to field forceNext 18–24 months
Sanzyme probiotic rankingBecome top 3 player (from 5th)No date given
Sanzyme profit₹100 Cr profit, implying 15–16% return on acquisition3–4 years
Sporlac brand rankEnter top 300 brandsNext 8–10 months
Azmarda brand rankEnter top 300 brandsNext 8–12 months
Azmarda post-LOE volumesGo up 2–2.5x2–3 years post LOE (LOE: Nov–Dec 2022)
Operating EBITDA margin24% to 26% rangeNext one year (FY23)
US ANDA filingsFile 8–10 ANDAs (low volume, high value, niche)Next couple of years
CMO revenue contributionReach 15–20% of total revenue3–5 years
CMO business scaleDouble and triple the current ~$30 million business3–5 years
Sanzyme revenue growthLift from 8–9% to 15–16%"Coming time" (no specific date)

Key Metrics

MetricQ4 FY22
Revenue₹625 cr, +18% YoY
FY22 revenue₹2,400 cr, +19% YoY, ₹400 cr addition
India business growth30%
International business growthLow double-digit
Adjusted EBITDA₹164 cr, +32% YoY (₹124 cr in Q4 FY21)
Adjusted EBITDA margin25.5% to 26%
FY22 adjusted EBITDA₹634 cr, +13% YoY (₹560 cr in FY21)
FY22 gross marginCloser to 65%
FY22 PAT (reported)₹386 cr
FY22 tax rateCloser to 25%; Q4 lower due to mutual fund sales
India business rank23rd, up from 32nd in Oct 2020
India business market shareClose to 1%
Chronic portfolio contributionClose to 50%, up from 40% in FY2018-19
New product contribution4%, up from 1.5%
MR count2,500 across all three entities
Per person productivity (India)~₹5.6 lakhs, up from ~₹3.5 lakhs in FY2019
Sanzyme acquisition cost₹650 cr
Sanzyme acquired revenue₹140 cr, gross margin 70%+
Sanzyme market share (probiotics)7.5%, fifth largest player
Cilacar franchise₹300 cr
South Africa businessClose to ₹300 cr, 100% subsidiary
Russia business~$20 million
US businessClose to $30 million, 15 ANDAs
Cash from operations (FY22)~₹170 cr
Cash generated (FY22)~₹30 cr
FY23 EBITDA margin guidance24% to 26%
NPP portfolio (% of domestic revenue)25% to 30%